194
Views
13
CrossRef citations to date
0
Altmetric
Review

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

, , , &
Pages 821-826 | Published online: 08 Aug 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Goce Spasovski. (2015) Advances in pharmacotherapy for hyperphosphatemia in renal disease. Expert Opinion on Pharmacotherapy 16:17, pages 2589-2599.
Read now

Articles from other publishers (12)

Jack Kit-Chung Ng, Gordon Chun-Kau Chan, Kevin Ka-Ho Kam, Na Tian, Win Hlaing Than, Phyllis Mei-Shan Cheng, Man-Ching Law, Wing-Fai Pang, Cheuk-Chun Szeto & Philip Kam-Tao Li. (2022) The Impact of Volume Overload on the Longitudinal Change of Adipose and Lean Tissue Mass in Incident Chinese Peritoneal Dialysis Patients. Nutrients 14:19, pages 4076.
Crossref
Paolo Monardo & Antonio Lacquaniti. (2022) Clinical Management of Hemodialyzed Patients: From Pharmacological Interventions to Advanced Technologies. Journal of Clinical Medicine 11:15, pages 4310.
Crossref
Roopa Satyanarayan Basutkar, Resia Varghese, Nina Kallanthanath Mathew, Prithika Sankar Indira, Balasubramaniam Viswanathan & Ponnusankar Sivasankaran. (2021) Systematic review and meta‐analysis of potential pleiotropic effects of sevelamer in chronic kidney disease: Beyond phosphate control. Nephrology 27:4, pages 337-354.
Crossref
M. Mar Perez, Miguel D. Ferrer, Marta Lazo-Rodriguez, Ana Zeralda Canals, Elisenda Banon-Maneus, Josep M. Campistol, Stephan Miller, Rekha Garg, Alex Gold, Carolina Salcedo & Joan Perelló. (2020) A novel assay to measure calcification propensity: from laboratory to humans. Scientific Reports 10:1.
Crossref
Carolina Salcedo, Pieter H. Joubert, Miguel D. Ferrer, Ana Z. Canals, Francisco Maduell, Vicens Torregrosa, Josep Maria Campistol, Raquel Ojeda & Joan Perelló. (2019) A phase 1b randomized, placebo‐controlled clinical trial with SNF472 in haemodialysis patients. British Journal of Clinical Pharmacology 85:4, pages 796-806.
Crossref
Eniva Miladi Fernandes Stumm, Rosane Maria Kirchner, Laura de Azevedo Guido, Eliane Raquel Rieth Benetti, Angélica Gonçalves Silva Belasco, Ricardo de Castro Cintra Sesso & Dulce Aparecida Barbosa. (2017) Intervenção educacional de enfermagem para redução da hiperfosfatemia em pacientes em hemodiálise. Revista Brasileira de Enfermagem 70:1, pages 31-38.
Crossref
Fateme Shamekhi Amiri. (2015) Contemporary management of phosphorus retention in chronic kidney disease: a review. Clinical and Experimental Nephrology 19:6, pages 985-999.
Crossref
Toru Sanai, Hideo Tada, Takashi Ono & Toma Fukumitsu. (2014) Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis—sevelamer hydrochloride, calcium carbonate, and bixalomer. Hemodialysis International 19:1, pages 54-59.
Crossref
Zaw Thet, Aung Ko WIN, Eugenie Pedagogos, Jennifer Beavis, Sandra Crikis & Craig Nelson. (2013) Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis. BMC Nephrology 14:1.
Crossref
Anjay Rastogi. (2013) Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Therapeutic Advances in Cardiovascular Disease 7:6, pages 322-342.
Crossref
Kazumichi Matsushita, Hidehiro Tabata, Kosaku Nitta & Kiichiro Tago. (2010) Prospective observational study of sevelamer hydrochloride and lanthanum carbonate-Effect of sevelamer hydrochloride on the acid-base equilibrium of patients on hemodialysis with citric acid dialysate. Nihon Toseki Igakkai Zasshi 43:9, pages 763-768.
Crossref
Kazumichi Matsushita, Hidehiro Tabata, Kosaku Nitta & Kiichiro Tago. (2010) The effects of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients with citrate dialysate. Nihon Toseki Igakkai Zasshi 43:4, pages 373-379.
Crossref